Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diuretic withdrawal and right heart changes in pulmonary hypertension
NL-OMON51476Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of furosemide and bumetanide in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Amsterdam University Medical Center. Primary endpoints: Right atrial end reservoir volume, Right atrial volume at end active emptying and 10 more. Started Jan 2023; status: recruiting.
02
Drugs
furosemidebumetanide
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON51476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51476.